Poliovirus type 2 (inactivated) (IPV2)

Inactivated poliovirus type 2 refers to the killed (inactivated) form of poliovirus serotype 2, one of three human poliovirus types (type 1, 2, and 3) from the genus Enterovirus, family Picornaviridae[1][6]. This is not a typical therapeutic target such as a receptor, enzyme, ion channel, or transporter, but rather a component or antigen in a vaccine used to induce immunity against poliovirus type 2. Inactivated poliovirus type 2 does not replicate and cannot cause disease, but when included in a vaccine formulation, it triggers an immune response that protects against infection and paralytic disease caused by wild or vaccine-derived poliovirus type 2 strains[1][6]. The term "inactivated poliovirus type 2" is not a molecular drug target—it is an immunogen in vaccines such as IPV (inactivated polio vaccine), which contains inactivated strains of all three poliovirus types[6][5]. The key mechanism of protective action is the induction of serum antibodies that prevent poliovirus from spreading to the central nervous system and resulting in paralysis[6][2]. Inactivated poliovirus vaccine does not induce strong mucosal immunity, so although it prevents disease, vaccinated individuals might still shed virus after exposure[2]. The concept of "inactivated poliovirus type 2" as a molecular or therapeutic target is therefore incorrect. It is accurately considered an inactivated viral antigen/vaccine component, not a druggable or endogenous target[6][7]. Key points: - This is not a cellular or protein target (receptor/enzyme); it is the inactivated virus used in vaccines[1][6]. - Not classified into standard molecular drug target families[6]. - Major clinical function is to prevent infection by poliovirus type 2 and its associated paralytic illness[1][6]. - Used in trivalent or bivalent IPV formulations for immunization[5][6]. - No drugs interact with inactivated poliovirus; it is itself the immunogen in vaccines[6]. - No known safety concerns associated specifically with the "target" itself; vaccine safety concerns relate to the formulation as a whole, with serious adverse reactions being extremely rare[6][7]. - The correct canonical name for a vaccine component is "Poliovirus type 2 (inactivated)" or "Inactivated poliovirus type 2." Conclusion: "Inactivated poliovirus type 2" is not a classical biotherapeutic target but a vaccine antigen, so using it as a target in the sense of a receptor/enzyme/etc. is incorrect[6].

Other names

Inactivated poliovirus type 2Poliovirus type 2 (inactivated)IPV type 2Type 2 inactivated poliovirus